GLPGF · Insider trading · 13F holders · Congress trades
Lakefront Biotherapeutics (GLPGF)
Who is buying and selling GLPGF: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 8
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $0
- Congress trades, 12 months
- 0
GLPGF at a glance
- No open-market insider purchases or sales of GLPGF were filed in the last 90 days.
- 8 13F filers hold GLPGF among their 50 largest positions, worth $847.4M combined, including Oleg Nodelman and David Einhorn. The biggest bets by portfolio weight are Prosight Management, LP (10.6%), Tang Capital Management LLC (5.2%) and Madison Avenue Partners, LP (4.5%). In their latest 13Fs, 0 managers opened a new position and 2 added to one.
- No member of Congress has disclosed a trade in GLPGF.
GLPGF insider trading
No open-market insider purchases or sales of GLPGF were filed in the last 90 days.
Who owns GLPGF? Hedge funds and superinvestors
8 13F filers hold GLPGF among their 50 largest positions, worth $847.4M combined, including Oleg Nodelman and David Einhorn. The biggest bets by portfolio weight are Prosight Management, LP (10.6%), Tang Capital Management LLC (5.2%) and Madison Avenue Partners, LP (4.5%). In their latest 13Fs, 0 managers opened a new position and 2 added to one.
Superinvestors holding GLPGF: Oleg Nodelman 2.5% · David Einhorn 0.4%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Gilead Sciences, Inc.Corporation | 30.3% | $500.2M | 16,707,477 | +0.0% shares | Q2 2026 |
| Tang Capital Management LLCHedge fund | 5.2% | $113.5M | 3,785,991 | +0.0% shares | Q2 2026 |
| Madison Avenue Partners, LPHedge fund | 4.5% | $103.4M | 3,447,807 | +39.9% shares | Q2 2026 |
| Prosight Management, LPHedge fund | 10.6% | $61.3M | 2,043,344 | +31.8% shares | Q2 2026 |
| Oleg NodelmanHedge fund | 2.5% | $50.0M | 1,667,119 | +0.0% shares | Q2 2026 |
| David EinhornSuperinvestor · Hedge fund | 0.4% | $14.5M | 482,746 | +0.0% shares | Q2 2026 |
| DAFNA Capital Management LLCHedge fund | 0.7% | $3.9M | 130,175 | +0.0% shares | Q2 2026 |
| Monaco Asset Management SAMAsset manager | 0.3% | $767K | 25,600 | -7.0% shares | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 8). Screen GLPGF in the grand portfolio →
GLPGF stock trades by members of Congress
No member of Congress has disclosed a trade in GLPGF.
GLPGF questions and answers
Are insiders buying GLPGF stock?
No open-market insider purchases or sales of GLPGF were filed in the last 90 days.
Which hedge funds own GLPGF?
8 13F filers hold GLPGF among their 50 largest positions, worth $847.4M combined, including Oleg Nodelman and David Einhorn. The biggest bets by portfolio weight are Prosight Management, LP (10.6%), Tang Capital Management LLC (5.2%) and Madison Avenue Partners, LP (4.5%). In their latest 13Fs, 0 managers opened a new position and 2 added to one.
Has Congress traded GLPGF?
No member of Congress has disclosed a trade in GLPGF.
Who is the largest holder of GLPGF?
Among 13F filers, Gilead Sciences, Inc. reports the largest GLPGF position, $500.2M (16,707,477 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Prosight Management, LP's: 10.6% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.